echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Lancet Neurology: Safety and Efficacy of Tiranezumab in the Treatment of Progressive Supranuclear Palsy: A Phase 2 Randomized Placebo Controlled Trial

    Lancet Neurology: Safety and Efficacy of Tiranezumab in the Treatment of Progressive Supranuclear Palsy: A Phase 2 Randomized Placebo Controlled Trial

    • Last Update: 2021-03-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Tau disease refers to the disorder of tau protein aggregation, which is heterogeneous in biochemistry, morphology and clinical manifestations.


    Tau disease refers to the disorder of tau protein aggregation, which is heterogeneous in biochemistry, morphology and clinical manifestations.


    This is a phase 2, multi-center, randomized, placebo-controlled, double-blind study conducted in 66 hospitals and clinics in multiple countries.


    diagnosis

    From December 12, 2016 to December 31, 2018, a total of 466 participants were screened and 378 participants were randomly divided into groups.


    In this phase 2 study of progressive supranuclear palsy, although Telavirumab was not effective in the treatment of progressive supranuclear palsy, the safety of all treatment groups was similar.


    Biomarker analysis showed that Tiranezumab binds to target cells.


    Höglinger, Günter UAhmed, Anwar et al.
    Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.
    The Lancet Neurology, Volume 20, Issue 3, 182-192 Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.